Severe 5‐fluorouracil toxicity caused by reduced dihydropyrimidine dehydrogenase activity due to heterozygosity for a G→A point mutation
- 1 June 1998
- journal article
- case report
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 21 (3) , 280-284
- https://doi.org/10.1023/a:1005384609289
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Inborn errors of pyrimidine degradation: Clinical, biochemical and molecular aspectsJournal of Inherited Metabolic Disease, 1997
- Subcellular localization of dihydropyrimidine dehydrogenaseClinical Biochemistry, 1997
- Subcellular Localization of Dihydropyrimidine DehydrogenaseBiological Chemistry, 1997
- A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiencyJournal of Inherited Metabolic Disease, 1996
- Identification and tissue-specific expression of a NADH-dependent activity of dihydropyrimidine dehydrogenase in man.1996
- Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytesBiochemical Pharmacology, 1995
- Human Polymorphism in Drug Metabolism: Mutation in the Dihydropyrimidine Dehydrogenase Gene Results in Exon Skipping and Thymine UracilureaDNA and Cell Biology, 1995
- Clinical and biochemical findings in six patients with pyrimidine degradation defectsJournal of Inherited Metabolic Disease, 1994
- Clinical Cardiotoxicity of 5‐FluorouracilThe Journal of Clinical Pharmacology, 1993
- Pigmentary Effects from the Protracted Infusion of 5-FluorouracilInternational Journal of Dermatology, 1991